

Table of Contents

Section 1. Introduction	1-1
1.1 Sources of Procedural Information	2
1.2 Investigator Responsibilities	3
1.3 Study Activation Process	4
1.3.1 Protocol Distribution	4
1.3.2 Development & CORE Review of Site-Specific Informed Consent Forms: English Version..	4
1.3.3 Development & CORE Review of Site-Specific Informed Consent Forms: Local Language Version(s) and Back-translation(s).....	4
1.3.4 IRB/EC Review	5
1.3.5 Protocol Registration.....	8
1.3.6 Site-Specific Study Activation	9
Section 2. Protocol.....	2-1
Section 3. Documentation Requirements	3-1
3.1 Essential Documents.....	2
3.2 Participant Research Records	3
3.2.1 Participant Research Record Content.....	3
3.2.2 Concept of Source Documentation.....	4
3.2.3 Document Organization	5
3.2.4 Chart Notes.....	6
3.2.5 DataFax and Non-DataFax Forms Provided by the SDMC	7
3.3 Record Retention Requirements	7
3.4 Product Dispensing and Accountability Records.....	7
3.5 Protocol Deviation Reporting	8
3.6 Ancillary Studies.....	9
3.7 Study Publications	9
Section 4. Participant Accrual	4-1
4.1 Accrual Plans and Targets	2
4.2 Recruitment.....	2
4.3 Screening	3
4.3.1 Assignment of Participant ID Numbers	4
4.3.2 Screening and Enrollment Timeframe.....	4
4.2.3 Screening and Enrollment Log.....	5
4.4 Informed Consent for Study Participation	5
4.4.1 Deliver Required Information in an Understandable Manner	6
4.4.2 Obtain Consent in a Setting Free of Coercion.....	7
4.4.3 Confirm Participant Comprehension.....	7
4.4.4 Document the Process	8
4.4.5 Informed Consent for Future Testing on Blood Specimens	9
4.4.6 Storage of Consent Forms	9

4.5	Eligibility Determination	10
4.5.1	Inclusion Criteria.....	10
4.5.2	Exclusion Criteria.....	11
4.5.3	Screening HIV Testing.....	11
4.6	Enrollment/Randomization.....	12
4.7	Screening and Enrollment Tracking	14
4.8	Screening and Enrollment Scenarios	15
4.8.1	Screening Timeframe/Re-screening	15
4.8.2	Laboratory Findings	15
4.8.3	Ineligibility at Randomization Visit.....	16
4.8.4	Participant Withdrawal.....	16

Section 5. Participant Follow-up.....5-1

5.1	Length of Study Participation	2
5.2	Intervention Visits.....	2
5.2.1	Intervention Visit Scheduling.....	2
5.2.2	Missed Intervention Visits.....	2
5.3	Follow-up Visit	4
5.3.1	Target Follow-up Visit Dates	5
5.3.2	Allowable Follow-up Visit Windows.....	5
5.3.3	Missed Follow-up Visits.....	6
5.3.4	Visits Conducted Over Multiple Days (“Split Visits”).....	6
5.4	Follow-up Visit Procedures	6
5.4.1	Assessments during Safety Phase.....	6
5.4.2	Routine Assessments	7
5.4.3	26 and 52 Week Visits.....	7
5.4.4	78, 104, 130 and 156 Week Visits.....	8
5.5	Visit Locations/Outreach Visits	9
5.6	Modified Follow-up Procedures	9
5.6.1	Early Study Drug Discontinuation	9
5.6.2	Pregnancy	10
5.6.3	Participant Seroconversion.....	14
5.6.4	Early Termination.....	14
5.6.5	Participant Transfers.....	15
5.6.6	Resumption of Study Participation after Withdrawal.....	16
5.7	Follow-up Visit Scenarios.....	16

Section 6. Visit Checklists.....6-1

6.1	Use of Checklists	2
6.2	Sequence of Procedures.....	2
6.3	Visit Checklists.....	3
6.3.1	Screening, Enrollment and Randomization.....	3
6.3.2	First 3 Days of Induction.....	7
6.3.3	Counseling Visits	10
6.3.4	Detoxification Arm.....	12
6.3.5	Substitution Arm	21

Section 7. Data Collection and Data Management.....7-1

7.1 DataFax Overview 2

7.2 DataFax Forms Completion..... 2

 7.2.1 Guidelines..... 3

 7.2.2 How to Mark Response Boxes 4

 7.2.3 How to Record Numbers 4

 7.2.4 How to Record Dates 5

 7.2.5 How to Record Time 6

 7.2.6 Data Corrections and Additions 7

 7.2.7 How to Handle Missing and Unknown Data..... 8

7.3 Rounding when recording lab values on CRFs..... 9

7.4 Assigning Severity Grades on CRFs..... 10

7.5 Site Review of DataFax Forms 11

7.6 Faxing DataFax Forms..... 11

7.7 Participant ID Numbers (PTID)..... 12

7.8 Visit Windows, Visit Codes, Missed and Interim Visits 12

 7.8.1 Visit Windows..... 12

 7.8.2 Visit Codes 12

 7.8.3 Interim Visits..... 14

 7.8.4 Missed Visits 14

7.9 HPTN 058 DataFax and non-DataFax Forms and Instructions 19

7.10 How to Complete Interviewer-administered Forms..... 23

 7.10.1 Interviewing Techniques 23

 7.10.2 Welcoming the Participant 23

 7.10.3 Asking Sensitive Questions 23

 7.10.4 Recording Participants’ Responses Verbatim 23

 7.10.5 Pacing the Interview 24

 7.10.6 Reading Items Aloud..... 24

 7.10.7 Instructions to the Interviewer..... 24

 7.10.8 Show Cards..... 24

 7.10.9 Probing 24

 7.10.10 Checking Your Work 25

Section 8. Retention8-1

8.1 Retention Definition..... 2

8.2 Retention Requirements..... 3

8.3 Retention Plan..... 3

8.4 Obtaining and Updating Locator Information 4

8.5 Participant Tracking Database 5

8.6 Retention Strategies 5

Section 9. Study Product Considerations for Non-Pharmacy Staff9-1

9.1 Study Product..... 2

 9.1.1 Study Product Temperature 2

 9.1.2 HPTN 058 Study Product 2

 9.1.3 Requirements Prior to Shipment to Sites 3

 9.1.4 Study Product Acquisition..... 3

 9.1.5 Study Product Accountability 4

9.2	Chain of Custody	4
9.3	Dispensing Study Product during On-Site Visits.....	4
	9.3.1 Dispensing from the Pharmacy to Clinic Staff	4
	9.3.2 Dispensing from the Pharmacy to Transporters	7
9.4	Dispensing for Take Home Doses	9
9.5	Dispensing from Mobile Units.....	10
9.6	Administration of the Participant-Specific Study Product.....	10

Section 10. Clinical and Counseling Procedures10-1

10.1	Screening Procedures.....	2
10.2	Initial Screening Visit	2
	10.2.1 Pre- and Post-test HIV Counseling	3
	10.2.2 Assessing Opioid Dependence	3
	10.2.3 Screening Laboratory Assessments	4
	10.2.4 Screening Medical History	4
	10.2.5 Pre-existing Conditions	5
	10.2.6 Concomitant Medications.....	5
	10.2.7 Screening Physical Exam	5
10.3	Drug- and Risk-Reduction Counseling.....	6
10.4	Follow-up Visits.....	6
	10.4.1 Assessments During Safety Phase.....	7
	10.4.2 Interim Medical History	7
	10.4.3 Follow-up Concomitant Medications	7
	10.4.4 Symptom-directed Physical Exam.....	8
	10.4.5 Follow-up Laboratory Assessments	8
10.5	Access to HIV-Related Care	9

Section 11. Laboratory Procedures11-1

11.1	Biohazard Containment	11-2
11.2	Specimen Labeling.....	2
11.3	Use of LDMS	3
	11.3.1 LDMS Specimen Tracking Sheets.....	4
	11.3.2 LDMS Specimen Processing and Storage	6
	11.3.3 LDMS Quality Control Monitoring.....	6
11.4	Required Laboratory Assays.....	7
	11.4.1 Remote Specimen Testing	9
	11.4.2 HIV Testing	9
	11.4.3 HCV Testing.....	14
	11.4.4 Hepatitis B Testing	15
	11.4.5 Hematology and Chemistry Testing	16
	11.4.6 Plasma Archive.....	17
	11.4.7 Urine Testing	18
11.5	Quality Control and Quality Assurance Procedures	19
11.6	Shipping Specimens to the HPTN Network Laboratory.....	19
11.7	Laboratory Monitoring.....	20

Section 12. Adverse Event Reporting and Safety Monitoring12-1

12.1 Definitions and General Reporting Guidance 2
 12.1.1 Adverse Events (AEs) 2
 12.1.2 Serious Adverse Events (SAEs) 2
 12.1.3 Events that meet the DAIDS Criteria for Expedited Reporting (EAEs) 3
12.2 Adverse Event Relationship Assessment 5
12.3 Adverse Event Severity Grading 7
12.4 Adverse Event Terminology 7
12.5 Adverse Events Associated with BUP/NX 8
12.6 Lab Abnormalities 8
12.7 Follow-up Information on Adverse Events 9
12.8 Reporting Recurrent Adverse Events 10
12.9 Social Harms 10
12.10 HPTN 058 Safety Review and Oversight 11
12.11 Toxicity and Dosing Management Procedures 12
12.12 Safety Distributions from DAIDS 12

Section 13. Reporting Plan13-1

13.1 Purpose of Reporting Plan 1
13.2 Procedures 1
13.3 Reports 2
 13.3.1 Enrollment/Retention Report 3
 13.3.2 Data Quality Control (QC) Report 4
 13.3.3 Clinical Quality Control Report 5
 13.3.4 Data Management Quality Report 6
 13.3.5 Unresolved Serious Adverse Events Report 7
 13.3.6 Protocol Safety Review Team Report 8
 13.3.7 Pregnancy Report 9
 13.3.8 Study Monitoring Committee (SMC) Report 10
 13.3.9 Data Safety and Monitoring Board (DSMB) Report 11

Appendices

- A. Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance
- B. DAIDS SOP for Essential Documents
- C. DAIDS SOP for Source Documentation
- D. Toxicity Tables DAIDS AE Grading Table
- E. EAE Manual
- F. DataFax and non-DataFax Forms
- G. BUP/NX Treatment Manual
- H. HPTN 058 Counseling Manual

Tables

Table 1-1 IRB/EC Submissions Required Before Study Initiation 1-6
Table 1-2 IRB/EC Submissions Required During Study Conduct and At Completion 1-7
Table 3-1 Suggested Filing Structure for HPTN 058 Essential Documents 3-10
Table 3-2 Guide to Required Case History Elements and Source Documents 3-13

Table 3-3 Protocol Deviation Form	3-16
Table 3-4 Ancillary Study Application	3-18
Table 4-1 Timing of Screening and Enrollment Assessments for HPTN 058	4-4
Table 4-2 Sample HPTN 058 Screening and Enrollment Log.....	4-17
Table 4-3 Sample Informed Consent Coversheet for HPTN 058	4-19
Table 4-4 Pre-Screening Sample Form.....	4-20
Table 5-1 Missed Intervention Visits.....	5-4
Table 7-1 HPTN 058 visit by Type and Visit codes	7-15
Table 11-1 Specimen Collection and Storage by Visit.....	11-8
Table 12-1 Adverse Event Reporting and Additional Documentation Requirements	12-6
Table 12-2 Adverse Events (Excerpt from Package Insert).....	12-8

Figures

Figure 4-1 Sample HPTN 058 Randomization Envelope	4-13
Figure 4-2 Sample Opened HPTN 058 Clinic Randomization Envelope.....	4-13
Figure 5-1 Sample Pregnancy Management Worksheet for HPTN 058.....	5-12
Figure 8-1 Monthly Retention Targets for HPTN 058.....	8-3
Figure 9-1. HPTN 058 Record of Receipt of Participant-Specific Study Product.....	9-6
Figure 9-2. HPTN 058 Daily Record of Administration of Participant-Specific Study Product.....	9-6
Figure 9-3. HPTN 058 Record of Return of Participant-Specific Study Product	9-7
Figure 9-4. HPTN 058 Daily Transporter Log (from Transporter to Clinic Staff)	9-8
Figure 9-5. HPTN 058 Daily Transporter Log (from Clinic Staff to Transporter)	9-9
Figure 11-1 Sample Specimen Tracking Sheet.....	11-5
Figure 11-2 HIV Antibody Testing Algorithm – Screening	11-12
Figure 11-3 HIV Antibody Testing Algorithm – Follow-up	11-13
Figure 11-4 HCV Antibody Testing Algorithm – Sequential Analysis.....	11-15
Figure 11-5 HCV Antibody Testing Algorithm – Parallel Analysis.....	11-16

Other

Participant Locator Information Sample.....	8-8
HPTN 058 Protocol Safety Review Team Plan	12-14
HPTN 058 Protocol Safety Review Team Query Form.....	12-17